# US Bone Biopsy Market > US Bone Biopsy Market Research Report: Size, Share, Trend Analysis By Types (Needle Biopsy, Open Biopsy), By Guided (MRI-Guided, CT-Guided), and By End Users (Hospitals and Clinics, Surgical Centers, Others) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 8.39% - **2024:** $ 201.6 Million - **2025:** $ 218.51 Million - **2035:** $ 489 Million - **Key Players:** BD (US), Medtronic (US), Boston Scientific (US), Stryker (US), Smith & Nephew (GB), Hologic (US), Terumo (JP), Cook Medical (US), Biopsy Sciences (US) **Report ID:** MRFR/HC/51270-HCR · **Pages:** 200 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** August 07, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-bone-biopsy-market-53031 --- ## Market Summary ## **US Bone Biopsy Market Overview** As per MRFR analysis, the US Bone Biopsy Market Size was estimated at 190.4 (USD Million) in 2023.The US Bone Biopsy Market Industry is expected to grow from 201.6 (USD Million) in 2024 to 411.69 (USD Million) by 2035. The US Bone Biopsy Market CAGR (growth rate) is expected to be around 6.706% during the forecast period (2025 - 2035). ## **Key US Bone Biopsy Market Trends Highlighted** The US Bone Biopsy Market is experiencing several important trends driven by advancements in medical technology, rising demand for minimally invasive procedures, and an increasing prevalence of bone-related diseases such as cancer and osteoporosis. One key market driver is the growing geriatric population in the United States, which is more susceptible to these conditions and, consequently, requires more diagnostic assessments. Technological innovations, including the development of specialized biopsy needles and imaging techniques, are enhancing the efficiency and accuracy of procedures, thus fostering higher adoption rates among healthcare providers. Expanding access to these procedures in outpatient settings presents notable opportunities within this market. As part of value-based care initiatives and improving patient outcomes, healthcare systems in the US seek more affordable and less invasive treatment options. This not only improves recovery times but also decreases hospital stays, benefiting both patients and providers. More recently, the integration of digital solutions and telemedicine into biopsy procedures is on the rise. This includes remote imaging review and virtual consultations, which enhance patient experience and diagnostic precision. Furthermore, educational initiatives aimed at training healthcare professionals on the latest biopsy techniques and technologies are enhancing the overall standard of care in the US. As these trends evolve, the US Bone Biopsy Market is poised for continued growth while addressing the changing needs of the population and healthcare system. Source: Primary Research, Secondary Research, _Market Research Future_ Database, and Analyst Review ## **US Bone Biopsy Market Drivers** ### **Rising Incidence of Bone-related Diseases** The US Bone Biopsy Market Industry is experiencing growth driven primarily by the increasing incidence of bone-related diseases such as cancer and osteoporosis. According to the Centers for Disease Control and Prevention (CDC), approximately 54 million adults in the United States are affected by low bone mass, putting them at increased risk for osteoporosis-related fractures. Furthermore, the American Cancer Society reports that in 2022, an estimated 1.9 million new cancer cases were diagnosed, with bone cancers such as multiple myeloma expected to see a rise. This surge in the prevalence of diseases requiring bone biopsies forms a substantial driver for market expansion as healthcare providers seek to confirm diagnoses effectively and quickly, illustrating the intertwined relationship between disease incidence and the demand for diagnostic procedures in the US Bone Biopsy Market Industry. ### **Technological Advancements in Biopsy Techniques** Technological advancements are driving the growth of the US Bone Biopsy Market Industry by improving the efficiency and accuracy of biopsy procedures. Innovations such as minimally invasive techniques, advanced imaging technologies, and the use of automated biopsy systems are evolving how procedures are conducted. Reports from the Food and Drug Administration (FDA) indicate that several new device approvals have emerged over the last few years, such as higher precision and lower complication rate devices. This evolution in technology allows for more accurate diagnosis and treatment, contributing to the overall growth of the market. Moreover, established organizations like Medtronic and Boston Scientific are actively investing in Research and Development (R&D) to enhance these technologies, thus bolstering the industry's capacity for advanced diagnostics. ### **Increasing Demand for Personalized Medicine** There is a growing demand for personalized medicine, which is driving the US Bone Biopsy Market Industry forward. The National Institutes of Health (NIH) illustrates that personalized medicine allows healthcare providers to tailor treatments based on individual patients’ genetic profiles and disease characteristics. This customization is leading to more effective treatments and improved patient outcomes. The prevalence of bone biopsies has significantly increased as these procedures facilitate genomic and molecular testing of tumor samples, which is crucial for personalized therapy approaches. With more healthcare institutions adopting precision medicine practices, the demand for bone biopsies is expected to rise substantially. Additionally, organizations like the American Association for Cancer Research are advocating for the integration of personalized approaches in clinical practice, reinforcing the market's growth potential. ### **Growing Awareness and Acceptance of Diagnostic Procedures** Growing public awareness and acceptance of diagnostic procedures, including bone biopsy, are substantially propelling the US Bone Biopsy Market Industry. Increased advocacy and educational initiatives by organizations such as the American Society of Clinical Oncology have heightened awareness regarding the importance of early diagnosis in combating cancer and bone diseases. The National Cancer Institute highlights that early detection can significantly increase the survival rates for various cancers, including bone-related malignancies. As a result, patients are more informed and proactive in seeking these diagnostic procedures. This shift towards patient-initiated demand is expected to increase the volume of procedures performed, thereby driving market growth over the next few years. ## **US Bone Biopsy Market Segment Insights** ### **Bone Biopsy Market Type Insights** The US Bone Biopsy Market is significantly shaped by its Type segmentation, which primarily encompasses Needle Biopsy and Open Biopsy. Needle Biopsy has emerged as a preferred choice among healthcare professionals due to its minimally invasive nature, which greatly reduces patient recovery time and associated complications compared to more invasive procedures. This method is pivotal in obtaining bone marrow samples, aiding in the diagnosis of various bone conditions, including cancers and hematologic disorders. As technological advancements continue to enhance the precision and efficacy of Needle Biopsy techniques, their application is expected to rise further, reflecting the current preferences in clinical settings. In contrast, Open Biopsy represents a more traditional approach, often utilized when deeper tissue samples are required or when Needle Biopsy is deemed insufficient. This procedure, although more invasive, plays a critical role in specific clinical scenarios, particularly where comprehensive tissue assessment is essential. While it may involve longer recovery periods and higher risks, Open Biopsy remains a vital option in the biopsy arsenal, thus ensuring that healthcare providers can choose the most suitable method based on patient needs and specific diagnostic requirements. Noteworthy trends in the US Bone Biopsy Market indicate a growing inclination towards less invasive procedures that promise shorter downtime, underscoring the importance of Needle Biopsy. Moreover, as awareness surrounding the effectiveness of early diagnosis and timely intervention escalates, both Needle Biopsy and Open Biopsy continue to gain traction. The interplay between these techniques and advancements in imaging technologies enhances the overall diagnostic landscape of bone-related conditions in the US. As the population ages and the incidence of bone diseases increases, the demand for efficient and reliable biopsy techniques is expected to grow, further propelling these segment dynamics. The evolving nature of the US Bone Biopsy Market exemplifies the broader trends in surgical methods, with a clear shift towards procedures that prioritize patient comfort and safety while maintaining diagnostic accuracy. Market growth will be increasingly influenced by innovations within each segment, addressing the specific needs of clinicians and patients alike, thereby solidifying their relevance in routine clinical practice. Source: Primary Research, Secondary Research, _Market Research Future_ Database, and Analyst Review ### **Bone Biopsy Market Guided Insights** The Guided segment of the US Bone Biopsy Market is gaining traction due to advancements in imaging technologies and their growing applications in diagnosing bone-related ailments. This segment includes MRI-Guided and CT-Guided biopsies, both of which are critical for obtaining precise tissue samples with minimal discomfort and injury. MRI-Guided techniques are notable for their ability to visualize soft tissue structures and tumors in real-time, thereby improving the accuracy of diagnostics. Meanwhile, CT-Guided biopsies are widely utilized due to their effectiveness in targeting hard-to-reach lesions, further driving the demand for these imaging methods in clinical settings. The integration of these guided approaches allows for enhanced procedural precision, which is vital in oncology and infectious disease cases. With the increasing prevalence of bone disorders and the demand for minimally invasive procedures in the United States, the Guided segment is positioned for significant growth. Overall, the US Bone Biopsy Market continues to evolve, with innovation and technology shaping its future trajectory. ### **Bone Biopsy Market End User Insights** The US Bone Biopsy Market is experiencing notable growth, particularly among various End User segments, including Hospitals and Clinics, Surgical Centers, and Others. Within this market, Hospitals and Clinics play a pivotal role as they are primary locations for diagnostic and interventional procedures related to bone conditions, leveraging advanced technology and skilled healthcare professionals. Surgical Centers are increasingly becoming significant as they offer specialized services and cater to outpatient needs, providing efficient and timely care. The Others segment includes various specialized facilities that contribute to patient care in unique ways. The demand for bone biopsy procedures in the US is driven by an increasing prevalence of bone-related diseases, advancements in imaging technologies, and the growing emphasis on early diagnosis and treatment. Additionally, the aging population in the US presents an opportunity for market growth as older individuals are more prone to conditions requiring biopsy procedures. Overall, the segmentation within the US Bone Biopsy Market highlights the diverse landscape of healthcare facilities that are essential in managing patient needs and driving market dynamics. ## **US Bone Biopsy Market Key Players and Competitive Insights** The US Bone Biopsy Market showcases a dynamic landscape characterized by a range of prominent players and emerging companies striving for a competitive edge. Key factors driving competition include technological advancements, product innovation, and the growing prevalence of bone-related disorders, which elevate the demand for effective diagnostic techniques. As companies focus on enhancing the quality of their offerings, customer preferences are shifting towards minimally invasive procedures and increased diagnostic accuracy. The competitive insights reveal a market where leading firms are leveraging both strategic partnerships and mergers to bolster their position, while new entrants challenge established players with innovative solutions and cost-effective options. The collaboration between various stakeholders, including healthcare providers, technology firms, and research institutions, is vital in shaping market dynamics and driving growth. Biopsy Sciences has positioned itself as a significant player in the US Bone Biopsy Market through its commitment to developing refined biopsy devices that cater to the specific needs of healthcare professionals and their patients. The company's strength lies in its robust product portfolio, comprising advanced biopsy needles and access devices designed for targeted bone sampling. Biopsy Sciences prioritizes user experience, ensuring that their products not only meet clinical requirements but also enhance procedural efficiency. With a strong focus on research and development, the company stays ahead of the curve by integrating feedback from healthcare practitioners and adapting its offerings to meet evolving standards. The firm's reputation for reliability and quality has solidified its presence in the market, enabling it to attract a loyal customer base and expand geographically within the United States. Cure Medical distinguishes itself in the US Bone Biopsy Market with a focus on high-quality medical devices and innovative solutions designed for optimal patient care. Known for its commitment to accessibility and performance, Cure Medical offers a range of products that include specialized biopsy kits and related instruments, which facilitate accurate and effective bone sampling. The company has strived to build a strong market presence through strategic collaborations, enhancing its distribution networks, and ensuring that its products reach a broad audience, including hospitals and outpatient surgical centers. Cure Medical has demonstrated growth through strategic mergers and partnerships, allowing it to reinforce its core competencies while expanding its technological capabilities. The emphasis on producing safe and effective medical devices, combined with an adaptive business strategy, positions the company favorably within the competitive landscape of the US Bone Biopsy Market. ### **Key Companies in the US Bone Biopsy Market Include:** - Biopsy Sciences - Cure Medical - ConMed - Cook Medical - Neusoft Medical Systems - Boston Scientific - Smith & Nephew - [BD](https://www.bd.com/en-us/products-and-solutions/products/product-families/bd-trek-powered-bone-biopsy-system) - Merit Medical - Stryker - Argon Medical Devices - Medtronic - Hologic - Terumo Corporation - Erlangen Medical ## **US Bone Biopsy Market Industry Developments** The US Bone Biopsy Market has witnessed notable developments in recent months. In August 2023, Biopsy Sciences launched a new minimally invasive bone biopsy device that enhances precision and reduces patient recovery time, addressing a growing trend towards less invasive procedures. Cure Medical and ConMed are collaborating on a Research and Development initiative to create innovative biopsy tools that improve diagnostic capabilities within the oncology sector.  Additionally, Merit Medical reported a significant increase in sales for their bone biopsy kits, driven by the rise in osteoporotic fractures among the aging population in the US, which is projected to influence market growth positively in the coming years. In terms of mergers and acquisitions, Stryker acquired the assets of a smaller competitor specializing in advanced biopsy technologies in July 2023, consolidating its position in the market.  Moreover, Hologic's expansion of its product line in September 2023 has bolstered its presence within the segmented market. The overall market valuation for companies like Medtronic and Boston Scientific is on the rise as they invest in innovative technologies and expand their service offerings, contributing to an increasingly competitive landscape in the US Bone Biopsy Market. ## **US Bone Biopsy Market Segmentation Insights** ### **Bone Biopsy Market Type Outlook** - Needle Biopsy - Open Biopsy ### **Bone Biopsy Market Guided Outlook** - MRI-Guided - CT-Guided ### **Bone Biopsy Market End User Outlook** - Hospitals & Clinics - Surgical Centers - Others ## Market Drivers ### Rising Healthcare Expenditure The increasing healthcare expenditure in the United States is a significant driver for the bone biopsy market. As healthcare budgets expand, there is a greater allocation of resources towards advanced diagnostic procedures, including bone biopsies. The Centers for Medicare & Medicaid Services (CMS) reported that national health spending is projected to grow at an average rate of 5.4% annually. This growth is expected to reach nearly $6 trillion by 2027. This financial commitment to healthcare is likely to enhance access to diagnostic services, thereby increasing the utilization of bone biopsies. Furthermore, as insurance coverage expands and more patients seek timely diagnoses, the bone biopsy market is poised for growth. This trend underscores the importance of financial investment in healthcare as a catalyst for advancements in diagnostic capabilities. ### Growing Awareness of Bone Health There is a notable increase in public awareness regarding bone health, which is positively influencing the bone biopsy market. Educational campaigns and initiatives aimed at promoting bone health have led to a greater understanding of the importance of early diagnosis and treatment of bone diseases. As individuals become more informed about conditions such as osteoporosis and bone tumors, they are more likely to seek medical advice and diagnostic procedures, including bone biopsies. This heightened awareness is reflected in the rising number of screenings and consultations, contributing to the growth of the bone biopsy market. Additionally, healthcare providers are increasingly emphasizing the need for proactive bone health management, further driving the demand for accurate diagnostic tools. This trend suggests a favorable environment for the continued expansion of the bone biopsy market. ### Advancements in Biopsy Techniques Innovations in biopsy techniques are playing a pivotal role in shaping the bone biopsy market. The introduction of technologies such as image-guided biopsies and needle biopsy systems has enhanced the precision and safety of the procedure. These advancements not only minimize patient discomfort but also improve diagnostic yield, making bone biopsies more appealing to both patients and healthcare providers. The market is witnessing a shift towards less invasive methods, which are associated with shorter recovery times and reduced complications. As a result, the adoption of these advanced techniques is expected to increase, potentially leading to a market growth rate of around 7% annually. This trend indicates a transformative phase for the bone biopsy market, as it adapts to the evolving needs of modern medicine. ### Increasing Demand for Diagnostic Accuracy The bone biopsy market is experiencing a notable surge in demand for diagnostic accuracy. As healthcare providers strive to enhance patient outcomes, the need for precise diagnostic tools becomes paramount. Bone biopsies are increasingly recognized for their ability to provide definitive diagnoses of various bone-related conditions, including malignancies and infections. This trend is reflected in the growing adoption of advanced imaging techniques and minimally invasive procedures, which are integral to the bone biopsy market. According to recent data, the market is projected to grow at a CAGR of approximately 6.5% over the next five years, driven by the increasing emphasis on accurate diagnostics in oncology and orthopedics. The rising awareness among healthcare professionals regarding the benefits of bone biopsies further propels this demand, indicating a robust future for the bone biopsy market. ### Aging Population and Associated Health Issues The demographic shift towards an aging population in the United States is significantly impacting the bone biopsy market. As individuals age, they become more susceptible to various bone diseases, including osteoporosis and bone cancers. This demographic trend is expected to drive the demand for bone biopsies, as early detection and accurate diagnosis are crucial for effective treatment. The U.S. Census Bureau projects that by 2030, approximately 20% of the population will be aged 65 and older, leading to an increased prevalence of bone-related health issues. Consequently, healthcare providers are likely to invest more in diagnostic procedures, including bone biopsies, to address the needs of this growing patient population. This shift suggests a promising outlook for the bone biopsy market, as it aligns with the broader trends in geriatric healthcare. ## Future Outlook The [Bone Biopsy Market](https://www.marketresearchfuture.com/reports/bone-biopsy-market-5341) is projected to grow at an 8.39% CAGR from 2025 to 2035, driven by technological advancements, increasing cancer prevalence, and rising demand for minimally invasive procedures. **New opportunities:** - Development of advanced imaging techniques for precise biopsy targeting. Expansion of telemedicine platforms for remote biopsy consultations. Investment in training programs for healthcare professionals on new biopsy technologies. By 2035, the bone biopsy market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Type: Needle Biopsy (Largest) vs. Open Biopsy (Fastest-Growing) In the US bone biopsy market, Needle Biopsy holds the largest market share due to its widespread adoption among healthcare providers. This method is favored for its minimally invasive nature and quick recovery time, making it a go-to choice for many clinicians and patients alike. Open Biopsy, while having a smaller share, is gaining traction as it offers comprehensive tissue sampling for more complex cases and provides reliable results which is essential for accurate diagnosis. Growth trends indicate a shift towards more advanced and minimally invasive techniques in the US bone biopsy market. As technological advancements enhance the precision and safety of Needle Biopsy, its popularity continues to rise. Simultaneously, Open Biopsy is emerging rapidly, driven by an increasing demand for accurate diagnoses in complicated cases. The evolving landscape of diagnostic imaging and increased awareness about bone-related diseases are key drivers contributing to the growth of these biopsy types. Biopsy Type: Needle Biopsy (Dominant) vs. Open Biopsy (Emerging) Needle Biopsy is characterized by its minimally invasive procedure, providing patient comfort and quicker recovery. This method has become dominant due to its effectiveness in sampling bone lesions with minimal tissue disruption. In contrast, Open Biopsy, while more invasive, is a robust option for challenging cases, allowing for larger tissue samples and firmer diagnostic certainty. As the US bone biopsy market evolves, both biopsy types will play crucial roles; Needle Biopsy will continue to serve as the dominant choice, whereas Open Biopsy is positioned as an emerging solution for more complex diagnostic requirements. ### By Guided: MRI-Guided (Largest) vs. CT-Guided (Fastest-Growing) The US bone biopsy market shows a significant distribution between MRI-Guided and CT-Guided techniques. MRI-Guided procedures command a substantial share as they provide superior imaging quality, enhancing diagnostic accuracy. In contrast, CT-Guided procedures are gaining traction due to their speed and efficiency, catering to a growing demand for minimally invasive techniques. The growth trends in this segment are primarily driven by technological advancements and increasing procedural volumes. MRI-Guided biopsies are seen as the gold standard for certain conditions, while CT-Guided techniques are emerging rapidly due to their cost-effectiveness and shorter recovery times. This dynamic illustrates a clear shift in preferences within the US bone biopsy market, as healthcare providers look for optimal solutions. MRI-Guided (Dominant) vs. CT-Guided (Emerging) MRI-Guided biopsy serves as the dominant technique in the US bone biopsy market, mainly due to its enhanced imaging capabilities that allow for precise targeting of lesions, reducing the likelihood of complications. This technique is particularly favored in soft tissue evaluations and is often preferred in challenging diagnostic cases. Conversely, CT-Guided biopsies are emerging as a competitive alternative, especially in scenarios demanding quick and efficient sample acquisition. Their growing accessibility and the ability to perform these procedures in various settings contribute to their increasing popularity. While MRI-Guided procedures maintain a strong foothold, the rise of CT-Guided techniques reflects the market's shift towards minimally invasive options. ### By End User: Hospitals and Clinics (Largest) vs. Surgical Centers (Fastest-Growing) In the US bone biopsy market, Hospitals and Clinics hold the largest market share, benefiting from their extensive patient base and comprehensive services. This segment is well-established and plays a critical role in providing advanced medical care and ensuring accurate diagnoses. Surgical Centers have also emerged as a significant segment, leveraging convenience and outpatient services that attract a growing number of patients seeking less invasive procedures. The growth trends for these segments are driven by an increasing prevalence of bone ailments among the population and the rising demand for diagnostic accuracy. Additionally, advancements in biopsy techniques and technologies are enhancing patient outcomes, making both Hospitals and Clinics, and Surgical Centers vital players in the market's evolution. Hospitals and Clinics (Dominant) vs. Surgical Centers (Emerging) Hospitals and Clinics represent the dominant segment in the US bone biopsy market, characterized by their extensive resources and specialized staff that can support complex procedures. They often feature state-of-the-art imaging technology and are capable of managing a wide range of bone-related health issues. On the other hand, Surgical Centers are emerging as a valuable alternative, catering to the desire for outpatient procedures that reduce hospital stays and associated costs. This trend is bolstered by patients' preference for quicker recovery options, enhancing the appeal of Surgical Centers as they adapt to evolving healthcare needs. ## Competitive Benchmarking The bone biopsy market is currently characterized by a competitive landscape that is both dynamic and multifaceted. Key growth drivers include the increasing prevalence of bone-related diseases, advancements in biopsy technologies, and a growing emphasis on minimally invasive procedures. Major players such as BD (US), Medtronic (US), and Hologic (US) are strategically positioned to leverage these trends. BD (US) focuses on innovation in biopsy devices, emphasizing the development of advanced imaging technologies to enhance precision. Medtronic (US) is pursuing a strategy of regional expansion, particularly in underserved markets, while Hologic (US) is concentrating on partnerships to enhance its product offerings and market reach. Collectively, these strategies contribute to a competitive environment that is increasingly defined by technological advancement and strategic collaborations.In terms of business tactics, companies are increasingly localizing manufacturing to reduce costs and improve supply chain efficiency. The market structure appears moderately fragmented, with several key players holding significant market shares. This fragmentation allows for a diverse range of products and innovations, although it also intensifies competition among established and emerging companies. The collective influence of these key players shapes market dynamics, as they vie for leadership through innovation and strategic positioning. In October BD (US) announced the launch of a new line of biopsy needles designed to improve patient outcomes through enhanced precision and reduced recovery times. This strategic move is significant as it not only reinforces BD's commitment to innovation but also positions the company to capture a larger share of the growing demand for minimally invasive procedures. The introduction of these advanced devices is likely to enhance BD's competitive edge in the market. In September Medtronic (US) completed the acquisition of a smaller biotech firm specializing in bone health technologies. This acquisition is indicative of Medtronic's strategy to bolster its product portfolio and expand its capabilities in the bone biopsy segment. By integrating innovative technologies from the acquired firm, Medtronic aims to enhance its offerings and improve patient care, thereby strengthening its market position. In August Hologic (US) entered into a strategic partnership with a leading imaging technology company to develop next-generation imaging solutions for bone biopsies. This collaboration is poised to enhance Hologic's product line and provide healthcare professionals with advanced tools for accurate diagnosis and treatment. The partnership reflects a broader trend in the industry towards integrating cutting-edge technology to improve clinical outcomes. As of November current competitive trends in the bone biopsy market are increasingly influenced by digitalization, sustainability, and the integration of artificial intelligence (AI) into diagnostic processes. Strategic alliances are playing a crucial role in shaping the landscape, as companies seek to combine resources and expertise to drive innovation. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on technological advancements, supply chain reliability, and the ability to deliver superior patient outcomes. This shift underscores the importance of innovation and strategic partnerships in navigating the complexities of the market. ## Recent News & Developments The US Bone Biopsy Market has witnessed notable developments in recent months. In August 2023, Biopsy Sciences launched a new minimally invasive bone biopsy device that enhances precision and reduces patient recovery time, addressing a growing trend towards less invasive procedures. Cure Medical and ConMed are collaborating on a Research and Development initiative to create innovative biopsy tools that improve diagnostic capabilities within the oncology sector.  Additionally, Merit Medical reported a significant increase in sales for their bone biopsy kits, driven by the rise in osteoporotic fractures among the aging population in the US, which is projected to influence market growth positively in the coming years. In terms of mergers and acquisitions, Stryker acquired the assets of a smaller competitor specializing in advanced biopsy technologies in July 2023, consolidating its position in the market.  Moreover, Hologic's expansion of its product line in September 2023 has bolstered its presence within the segmented market. The overall market valuation for companies like Medtronic and Boston Scientific is on the rise as they invest in innovative technologies and expand their service offerings, contributing to an increasingly competitive landscape in the US Bone Biopsy Market. ## Report Scope | MARKET SIZE 2024 | 201.6(USD Million) | | --- | --- | | MARKET SIZE 2025 | 218.51(USD Million) | | MARKET SIZE 2035 | 489.0(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 8.39% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | BD (US), Medtronic (US), Boston Scientific (US), Stryker (US), Smith & Nephew (GB), Hologic (US), Terumo (JP), Cook Medical (US), Biopsy Sciences (US) | | Segments Covered | Type, Guided, End User | | Key Market Opportunities | Advancements in minimally invasive techniques enhance patient outcomes in the bone biopsy market. | | Key Market Dynamics | Technological advancements and regulatory changes drive innovation and competition in the bone biopsy market. | | Countries Covered | US | ## Frequently Asked Questions **Q: What was the market valuation of the US bone biopsy market in 2024?** A: The market valuation of the US bone biopsy market was $201.6 Million in 2024. **Q: What is the projected market valuation for the US bone biopsy market in 2035?** A: The projected market valuation for the US bone biopsy market is $489.0 Million in 2035. **Q: What is the expected CAGR for the US bone biopsy market during the forecast period 2025 - 2035?** A: The expected CAGR for the US bone biopsy market during the forecast period 2025 - 2035 is 8.39%. **Q: Which companies are considered key players in the US bone biopsy market?** A: Key players in the US bone biopsy market include BD, Medtronic, Boston Scientific, Stryker, Smith & Nephew, Hologic, Terumo, Cook Medical, and Biopsy Sciences. **Q: What are the two main types of bone biopsy procedures and their market values?** A: The two main types of bone biopsy procedures are Needle Biopsy, valued at $290.16 Million, and Open Biopsy, valued at $198.84 Million. **Q: How does the market for MRI-guided bone biopsies compare to CT-guided procedures?** A: The market for MRI-guided bone biopsies is projected at $200.0 Million, while CT-guided procedures are projected at $289.0 Million. **Q: What are the primary end-user segments for the US bone biopsy market?** A: Primary end-user segments include Hospitals and Clinics, valued at $192.0 Million, Surgical Centers at $144.0 Million, and Others at $153.0 Million. **Q: What market segment shows the highest projected growth in the US bone biopsy market?** A: The Needle Biopsy segment shows the highest projected growth, with a valuation of $290.16 Million. **Q: What is the significance of the US bone biopsy market's growth from 2024 to 2035?** A: The US bone biopsy market is expected to grow from $201.6 Million in 2024 to $489.0 Million in 2035, indicating robust demand. **Q: How do the market values of different biopsy types reflect industry trends?** A: The market values of Needle Biopsy and Open Biopsy reflect a trend towards minimally invasive procedures, with Needle Biopsy leading in valuation. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-bone-biopsy-market-53031*